As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
Published in 360Dx
Author: Kelsy Ketchum
Abstract:
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
In this conversation, Stan Glazer, Managing Director at Outcome, shares insights from his extensive experience in the life sciences industry.
Read MoreOutcome Capital Life Science Market Pulse April 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?